

Thursday, 8 August 2024

## 2024 ANNUAL GENERAL MEETING

Australian Clinical Labs Limited (ASX: ACL) (**ACL** or **Company**) confirms that the Company's 2024 Annual General Meeting (**AGM**) will be held on Friday, 25 October 2024 at 9am AEDT.

Full details of the agenda and the instructions to participate in the AGM will be provided in the notice of meeting, which will be released to the ASX and sent to ACL shareholders in due course.

In accordance with the Company's constitution:

1. any shareholder wishing to nominate themselves as a candidate for election as a director must serve a notice of nomination signed by that shareholder; and
2. any shareholder wishing to nominate another person as a candidate for election as a director must serve a notice of nomination signed by that shareholder and a consent to the nomination signed by that person,

on the Company at least 35 business days before the AGM, being by no later than 5:00pm AEST on 6 September 2024.

**– ENDS –**

This announcement was authorised for release to ASX by the Company Secretary of ACL.

For further information regarding this announcement, please contact:

### Investors

Eleanor Padman

Company Secretary

Email: [investors@clinicallylabs.com.au](mailto:investors@clinicallylabs.com.au)

Phone: +61 (0) 422 002 918

### About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.